Nuvation Bio (NUVB) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary

Commercial performance and market trends

• IBTROZI's first-line patient numbers are growing at about 35% quarter-over-quarter, with over 50% of patients now in the frontline setting as of Q1.

• The market remains under-penetrated, with only 110 out of 750 eligible patients per quarter receiving IBTROZI, indicating significant growth potential.

• Crizotinib and entrectinib use are declining, while IBTROZI is gaining share, especially due to its efficacy and tolerability profile.

• Increased physician familiarity and positive efficacy data are driving a shift from late-line to frontline use.

• Consensus for first-line IBTROZI patients is 130–140 for the year, with current trends supporting this target.

Competitive landscape and regulatory updates

• IBTROZI is expected to maintain a lead over zidesamtinib, which is seeking second-line approval, with IBTROZI already established in first-line.

• IBTROZI's first-line response rate is 90% and duration of response is 50 months, considered unprecedented in oncology.

• Zidesamtinib's data maturity and efficacy are viewed as less robust, with regulatory agencies prioritizing IBTROZI.

• Expansion into other ROS1-driven tumors is possible but not a primary commercial focus due to rarity.

Pipeline development and clinical studies

• Safusidenib is being advanced in multiple glioma subtypes, targeting areas not covered by vorasidenib, with studies designed for both high- and low-grade tumors.

• A post-vorasidenib failure study is planned, aiming for accelerated approval with as few as 50–80 patients if response rates exceed 20%.

• Grade 3 oligodendroglioma study is distinct from SIGMA, targeting 40–80 patients, with data expected next year.

• Multiple sites are being opened to accelerate enrollment and data generation.